Search for drugs:
Typing the drug name to query
MANNITOL
DIR Classification
Classification:Moderate-DIQT concern
Severity Score:3.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- WARNINGS AND PRECAUTIONS
- Fluid and Electrolyte Imbalances, Hyperosmolarity
- Imbalances that may result from Mannitol Injection administration include:
- Hypo/hyperkalemia. The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, agents that may cause QT prolongation, neuromuscular blocking agents) [see DRUG INTERACTIONS (7.4)].
- DRUG INTERACTIONS
- Drugs Affected by Electrolyte Imbalances
- The development of electrolyte imbalances (e.g., hyperkalemia, hypokalemia) associated with mannitol administration may result in cardiac adverse reactions in patients receiving drugs that are sensitive to such imbalances (e.g., digoxin, drugs that prolong the QT interval, neuromuscular blocking agents) [see WARNINGS AND PRECAUTIONS (5.4)]. During and following Mannitol Injection infusion, monitor serum electrolytes and discontinue Mannitol Injection if cardiac status worsens [see WARNINGS AND PRECAUTIONS (5.5)].
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
1692
38379895
Odds Ratio = 0.0
Drug Property Information
ATC Code(s):
- R05CB16 - mannitol
- R05CB - Mucolytics
- R05C - "EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS"
- R05 - COUGH AND COLD PREPARATIONS
- R - RESPIRATORY SYSTEM
- A06AD16 - mannitol
- A06AD - Osmotically acting laxatives
- A06A - LAXATIVES
- A06 - LAXATIVES
- A - ALIMENTARY TRACT AND METABOLISM
- B05BC01 - mannitol
- B05BC - Solutions producing osmotic diuresis
- B05B - I.V. SOLUTIONS
- B05 - BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B - BLOOD AND BLOOD FORMING ORGANS
- B05CX04 - mannitol
- B05CX - Other irrigating solutions
- B05C - IRRIGATING SOLUTIONS
- B05 - BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B - BLOOD AND BLOOD FORMING ORGANS
- V04CX04 - mannitol
- V04CX0 -
- V04CX - Other diagnostic agents
- V04C - OTHER DIAGNOSTIC AGENTS
- V04 - DIAGNOSTIC AGENTS
- V - VARIOUS
Active Ingredient:MANNITOL
Active Ingredient UNII:3OWL53L36A
Drugbank ID:DB00742
PubChem Compound:6251
CTD ID:D008353
PharmGKB:PA450320
CAS Number:69-65-8
Dosage Form(s):injection, solution
Route(s) Of Administrator:intravenous
Daily Dose:
- 800.0 mg/day R05CB16
Chemical Structure: 
SMILE Code:
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
Reference
1: Plasma Hyperosmolality Prolongs QTc Interval and Increases Risk for Atrial Fibrillation in Traumatic Brain Injury Patients.
[Dabrowski Wojciech,Siwicka-Gieroba Dorota,Robba Chiara,Badenes Rafael,Bialy Mateusz,Iwaniuk Paulina,Schlegel Todd T,Jaroszynski Andrzej]J Clin Med,2020 Apr 30;9(5):1293. PMID: 32365845
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.